Transplantation of bone marrow mesenchymal stem cells preconditioned with hydrogen sulfide in the treatment of rat myocardial infarction

doi:10.3969/j.issn.2095-4344.2013.49.011

Abstract

Abstract:

BACKGROUND: Bone marrow mesenchymal stem cells (BMSCs) transplantation can promote cardiac repair after myocardial infarction, but it has been limited by the low cell survival rate.
OBJECTIVE: To study the effect of hydrogen sulfide (H₂S) on the BMSCs transplantation for treatment of myocardial infarction.
METHODS: BMSCs were separated and cultivated form Sprague-Dawley rats weighing (100±20) g. The 4th generation cells were used for later experiment, and marked by DAPI at 2 hours before use. Fifty male Sprague-Dawley rats, weighing (200±20) g had been divided into five groups: Sham group (n=10) and four transplantation groups: BMSCs (n=10), H₂S-BMSCs (n=10), H₂S (n=10), normal saline (n=10). The myocardial infarction model of four groups was established except of sham group (only thread without ligation). The cardiac function was measured by echocardiogram at 4 weeks after cell transplantation. The collagen in the infarction area was tested by Masson staining.
RESULTS AND CONCLUSION: Severe myocardial fibrosis was found in the normal saline group, with no myocardial regeneration in the infarct area. H₂S-BMSCs group had less collagen and more cardiac muscle tissue than BMSCs or H₂S groups. Left ventricular ejection fraction and left ventricular fractional shortening of the H₂S-BMSCs group were significantly higher than those of the BMSCs or H₂S groups (P < 0.05). The cells survival rate and cardiac function of myocardial infarction rats can be promoted by H₂S-preconditioned BMSCs transplantation, which is superior to BMSCs or H₂S alone.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: stem cells, mesenchymal stem cells, stem cell transplantation, myocardial ischemia, echocardiography, stress

CLC Number:

R394.2

Xie Yang-jing, Wang Ai-ling, Guo Zeng, Li Cong-sheng, Wang Chun-miao, Hao Yu-yu. Transplantation of bone marrow mesenchymal stem cells preconditioned with hydrogen sulfide in the treatment of rat myocardial infarction[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(49): 8532-8538.

Figures/Tables 3

References

[1] Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102(20 Suppl 4): IV14-23.

[2] Puymirat E, Ducrocq G. [Comparison between European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association (ACC/AHA) guidelines for initial management of ST-elevation myocardial infarction (STEMI)]. Ann Cardiol Angeiol (Paris). 2013.

[3] Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2012;143(1): 4-34.

[4] Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829): 701-705.

[5] Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004;95(1): 9-20.

[6] Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98(18): 10344-10349.

[7] Anversa P, Cheng W, Liu Y, et al. Apoptosis and myocardial infarction. Basic Res Cardiol. 1998;93 Suppl 3: 8-12.

[8] Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7(4): 430-436.

[9] Marelli D, Desrosiers C, el-Alfy M, et al. Cell transplantation for myocardial repair: an experimental approach. Cell Transplant. 1992;1(6): 383-390.

[10] Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1): 93-98.

[11] Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;6(3): 1066-1071.

[12] Wang R. Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J. 2002; 16(13):1792-1798.

[13] Olson KR, Donald JA. Nervous control of circulation--the role of gasotransmitters, NO, CO, and H2S. Acta Histochem. 2009; 111(3): 244-256.

[14] Yong QC, Cheong JL, Hua F, et al. Regulation of heart function by endogenous gaseous mediators-crosstalk between nitric oxide and hydrogen sulfide. Antioxid Redox Signal. 2011;14(11): 2081-2091.

[15] Chen X, Jhee KH, Kruger WD. Production of the neuromodulator H2S by cystathionine beta-synthase via the condensation of cysteine and homocysteine. J Biol Chem. 2004;279(50): 52082-52086.

[16] Kamoun P. Endogenous production of hydrogen sulfide in mammals. Amino Acids. 2004;26(3): 243-254.

[17] Robert K, Vialard F, Thiery E, et al. Expression of the cystathionine beta synthase (CBS) gene during mouse development and immunolocalization in adult brain. J Histochem Cytochem. 2003;51(3): 363-371.

[18] Ishii I, Akahoshi N, Yu XN, et al. Murine cystathionine gamma-lyase: complete cDNA and genomic sequences, promoter activity, tissue distribution and developmental expression. Biochem J. 2004;381(Pt 1): 113-123.

[19] Zhao W, Zhang J, Lu Y, et al. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001;20(21): 6008-6016.

[20] Nagao M, Duenes JA, Sarr MG. Role of hydrogen sulfide as a gasotransmitter in modulating contractile activity of circular muscle of rat jejunum. J Gastrointest Surg. 2012;16(2): 334-343.

[21] Szabó G, Veres G, Radovits T, et al. Cardioprotective effects of hydrogen sulfide. Nitric Oxide. 2011;25(2): 201-210.

[22] Huang C, Kan J, Liu X, et al. Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of s-propargyl-cysteine on heart failure rats and molecular mechanisms. PLoS One. 2013;8(7): e69205.

[23] Yao LL, Huang XW, Wang YG, et al. Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenation-induced apoptosis by preventing GSK-3beta-dependent opening of mPTP. Am J Physiol Heart Circ Physiol. 2010;298(5): H1310-1319.

[24] Cao Y, Adhikari S, Ang AD, et al. Mechanism of induction of pancreatic acinar cell apoptosis by hydrogen sulfide. Am J Physiol Cell Physiol. 2006;291(3): C503-510.

[25] Baskar R, Li L, Moore PK. Hydrogen sulfide-induces DNA damage and changes in apoptotic gene expression in human lung fibroblast cells. FASEB J. 2007;21(1): 247-255.

[26] Wang T, Tang W, Sun S, et al. Intravenous infusion of bone marrow mesenchymal stem cells improves myocardial function in a rat model of myocardial ischemia. Crit Care Med. 2007;35(11): 2587-2593.

[27] Nardi NB, Camassola M. Isolation and culture of rodent bone marrow-derived multipotent mesenchymal stromal cells. Methods Mol Biol. 2011;698: 151-160.

[28] Tang YL, Zhao Q, Qin X, et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg. 2005;80(1): 229-236; 236-237.

[29] Xie X, Sun A, Zhu W, et al. Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats. Tohoku J Exp Med. 2012;226(1): 29-36.

[30] Dai W, Hale SL, Martin BJ, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation. 2005;112(2): 214-223.

[31] Nygren JM, Jovinge S, Breitbach M, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med. 2004;10(5): 494-501.

[32] Hu X, Yu SP, Fraser JL, et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008; 135(4): 799-808.

[33] Tang G, Wu L, Liang W, et al. Direct stimulation of K(ATP) channels by exogenous and endogenous hydrogen sulfide in vascular smooth muscle cells. Mol Pharmacol. 2005;68(6): 1757-1764.

[34] Predmore BL, Lefer DJ. Development of hydrogen sulfide-based therapeutics for cardiovascular disease. J Cardiovasc Transl Res. 2010;3(5): 487-498.

[35] Calvert JW, Coetzee WA, Lefer DJ. Novel insights into hydrogen sulfide--mediated cytoprotection. Antioxid Redox Signal. 2010;12(10): 1203-1217.

[36] Gallyas F. Involvement of redox-signalling in endogenous hydrogen sulfide production. Br J Pharmacol. 2012;166(8): 2228-2230.

[37] Xie X, Sun A, Zhu W, et al. Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats. Tohoku J Exp Med. 2012;226(1): 29-36.

[38] Hu Y, Chen X, Pan TT, et al. Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. Pflugers Arch. 2008;455(4): 607-616.

[39] Shao JL, Wan XH, Chen Y, et al. H2S protects hippocampal neurons from anoxia-reoxygenation through cAMP-mediated PI3K/Akt/p70S6K cell-survival signaling pathways. J Mol Neurosci. 2011;43(3): 453-460.